Jolie Nguyen et al., 2024-09: Review of oral fenbendazole pharmacokinetics and anticancer activity in humans and animals, which lists glycolysis inhibition and glucose-uptake downregulation among the reported mechanisms.
This review focuses on the pharmacokinetics of orally administered fenbendazole and its promising anticancer biological activities, such as inhibiting glycolysis, down-regulating glucose uptake, inducing oxidative stress, and enhancing apoptosis in published experimental studies.
Jolie Nguyen et al., 2024-09: Review of oral fenbendazole pharmacokinetics and anticancer activity in humans and animals, which lists glycolysis inhibition and glucose-uptake downregulation among the reported mechanisms. Study type: narrative review. N: not applicable. Country: USA (Nimni-Cordoba laboratory, USC, with Vietnamese co-authors). Dose: not applicable (reviews others). Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: not applicable. The review states that fenbendazole is not approved by the FDA or EMA and that human pharmacokinetics are not well documented – a limitation recorded in the C8 rows. Also filed as FBC-40, FBD-16, FBE-10 (claims C1, C2, C3, C8). Study type: review.
